Puma Biotechnology vs Rhythm Pharmaceuticals
Puma Biotechnology is the larger business, with $228m of revenue in fiscal 2025 against $190m for Rhythm Pharmaceuticals (1.2 times as much). Rhythm Pharmaceuticals grew faster (45.8% against -0.9%). Puma Biotechnology kept more of each dollar of sales as profit: a net margin of 13.6% against -103.6%. Puma Biotechnology carries less debt relative to equity (17.4% against 77.8%).
| Latest fiscal year | Puma BiotechnologyPBYI, 2025 | Rhythm PharmaceuticalsRYTM, 2025 |
|---|---|---|
| Revenue | $228m | $190m |
| Revenue growth | -0.9% | 45.8% |
| Net income | $31.1m | −$197m |
| Operating margin | 16.3% | -101.2% |
| Net margin | 13.6% | -103.6% |
| Return on equity | 28.0% | — |
| Free cash flow | $41.7m | −$117m |
| Cash | $29.6m | $54.3m |
| Total debt | $22.7m | $108m |
| Debt to equity | 17.4% | 77.8% |
| Dividend per share | — | — |
| Dividend yield | — | — |
| Share buybacks | — | — |
| Employees | 179 | 414 |
| Market value | $520m | $6.43bn |
| Price vs our value range | Below our value range | — |
| Moat score | 47 (Moderate) | 25 (Weak) |
| Insider trades, 12 months | 0 buys, 17 sales | 0 buys, 50 sales |